TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. Recent studies have shown that many AML LSC-specific surface antigens could be such candidates. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, except for acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In mouse models reconstituted with human AML LSCs or human hematopoietic stem cells, a human TIM-3 mouse IgG2a antibody with complement-dependent and antibody-dependent cellular cytotoxic activities eradicates AML LSCs in vivo but does not affect normal human hematopoiesis. Thus, TIM-3 is one of the promising targets to eradicate AML LSCs.

Original languageEnglish
Pages (from-to)118-123
Number of pages6
JournalAnnals of the New York Academy of Sciences
Volume1266
Issue number1
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Mucin-3
T-cells
Stem cells
Acute Myeloid Leukemia
Immunoglobulins
Stem Cells
T-Lymphocytes
Hematopoietic Stem Cells
Therapeutics
Acute Promyelocytic Leukemia
Antibodies
Hematopoiesis
Surface Antigens
Cells

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

@article{5b76fe7a6b714f23998ddd0133b2140d,
title = "TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia",
abstract = "Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. Recent studies have shown that many AML LSC-specific surface antigens could be such candidates. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, except for acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In mouse models reconstituted with human AML LSCs or human hematopoietic stem cells, a human TIM-3 mouse IgG2a antibody with complement-dependent and antibody-dependent cellular cytotoxic activities eradicates AML LSCs in vivo but does not affect normal human hematopoiesis. Thus, TIM-3 is one of the promising targets to eradicate AML LSCs.",
author = "Yoshikane Kikushige and Koichi Akashi",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1749-6632.2012.06550.x",
language = "English",
volume = "1266",
pages = "118--123",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia

AU - Kikushige, Yoshikane

AU - Akashi, Koichi

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. Recent studies have shown that many AML LSC-specific surface antigens could be such candidates. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, except for acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In mouse models reconstituted with human AML LSCs or human hematopoietic stem cells, a human TIM-3 mouse IgG2a antibody with complement-dependent and antibody-dependent cellular cytotoxic activities eradicates AML LSCs in vivo but does not affect normal human hematopoiesis. Thus, TIM-3 is one of the promising targets to eradicate AML LSCs.

AB - Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. Recent studies have shown that many AML LSC-specific surface antigens could be such candidates. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, except for acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In mouse models reconstituted with human AML LSCs or human hematopoietic stem cells, a human TIM-3 mouse IgG2a antibody with complement-dependent and antibody-dependent cellular cytotoxic activities eradicates AML LSCs in vivo but does not affect normal human hematopoiesis. Thus, TIM-3 is one of the promising targets to eradicate AML LSCs.

UR - http://www.scopus.com/inward/record.url?scp=84865369927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865369927&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2012.06550.x

DO - 10.1111/j.1749-6632.2012.06550.x

M3 - Article

C2 - 22901263

AN - SCOPUS:84865369927

VL - 1266

SP - 118

EP - 123

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -